The company’s market value was nearly cut in half following trial results showing higher rates of treatment discontinuations ...

Anne White, a 30-year company veteran who previously led the company’s oncology unit, will step down as head of Lilly ...

While Vor provided no details on the results, the company is now evaluating a global trial of the drug in the chronic immune ...

The startup agreed to pay Fosun Pharma as much as $645 million for a drug in testing for multiple lung conditions, including ...

Miguel Fernández Alcalde, head of Merck KGaA’s U.S. arm, aims to “double down” on innovation. The company’s recent SpringWorks deal is just a start.

The FDA’s announcement of Papzimeos’ approval contained an unusual quote from newly reinstated CBER director Vinay Prasad. Elsewhere, Eli Lilly and Superluminal Medicines struck a deal.

Scientists say HHS’ decision to defund mRNA vaccine research will leave the country less prepared for pandemics, and make it ...

A refinancing deal will delay the maturity of $700 million in debt until 2030, allowing the company to “fully fund” its ...

Tough times in the industry are forcing changes in investment and governance that should result in a healthier sector, the ...

A new wave of Alzheimer’s research suggests semaglutide, widely known for diabetes and weight loss, could also slow cognitive ...

RFK Jr. has his sights set on increasing oversight and enforcement against drugmakers that run afoul of advertising laws.

The FDA clearance sets Novo’s medicine up for a market battle with Madrigal Pharmaceuticals’ fast-selling Rezdiffra.